<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Kaiser Permanente - HIV Testing Standard Operating Procedure</title>
    <style>
        body {
            font-family: Arial, sans-serif;
            margin: 20px;
            line-height: 1.6;
            color: #333;
        }
        h1 {
            color: #004d99;
            text-align: center;
            border-bottom: 3px solid #004d99;
            padding-bottom: 10px;
        }
        h2 {
            color: #006633;
            border-bottom: 2px solid #006633;
            padding-bottom: 5px;
        }
        h3 {
            color: #cc6600;
        }
        .header {
            background-color: #f0f8ff;
            padding: 15px;
            border-radius: 8px;
            margin-bottom: 20px;
        }
        .critical {
            background-color: #ffe6e6;
            border-left: 5px solid #ff4444;
            padding: 10px;
            margin: 10px 0;
        }
        .warning {
            background-color: #fff3cd;
            border-left: 5px solid #ffc107;
            padding: 10px;
            margin: 10px 0;
        }
        .info {
            background-color: #e7f3ff;
            border-left: 5px solid #007bff;
            padding: 10px;
            margin: 10px 0;
        }
        table {
            border-collapse: collapse;
            width: 100%;
            margin: 15px 0;
        }
        th, td {
            border: 1px solid #ddd;
            padding: 8px;
            text-align: left;
        }
        th {
            background-color: #f2f2f2;
            font-weight: bold;
        }
        .signature-section {
            background-color: #f9f9f9;
            padding: 15px;
            border-radius: 5px;
            margin-top: 20px;
        }
        .qc-table {
            background-color: #f8f9fa;
        }
        .competency-req {
            background-color: #e8f5e8;
            border: 1px solid #4caf50;
            padding: 10px;
            margin: 10px 0;
            border-radius: 5px;
        }
        .footer {
            text-align: center;
            margin-top: 30px;
            font-size: 0.9em;
            color: #666;
        }
    
    /* Kaiser Palette Harmonization */
    html, body {
        background-color: #f5f5f5;
        color: #333333;
    }
    body {
        min-height: 100vh;
        margin: 0 auto;
    }
    .container, .main-container, .kp-container, .content-wrapper {
        background-color: #ffffff;
        border-radius: 10px;
        box-shadow: 0 0 15px rgba(0,0,0,0.1);
        padding: 25px;
    }
    .header, .kp-header, header {
        border-bottom: 3px solid #0066cc;
        padding-bottom: 15px;
        margin-bottom: 20px;
    }
    .header h1, .kp-header h1, h1 {
        color: #0066cc !important;
    }
    h2 {
        color: #0066cc !important;
        border-bottom: 2px solid #0066cc;
        padding-bottom: 6px;
    }
    h3 {
        color: #004499 !important;
    }
    table {
        background-color: #ffffff !important;
        border-collapse: collapse;
    }
    th {
        background-color: #f0f8ff !important;
        color: #0066cc !important;
    }
    .toc {
        background-color: #f0f8ff;
        border-left: 4px solid #0066cc;
    }
    @media print {
        html, body {
            background-color: #ffffff !important;
        }
        .container, .main-container, .kp-container, .content-wrapper {
            box-shadow: none !important;
            border-radius: 0 !important;
            background-color: #ffffff !important;
        }
    }
</style>
</head>
<body>

<div class="header">
    <h1>Optimized Kaiser Permanente Laboratory SOP Template</h1>
    <h1>Human Immunodeficiency Virus (HIV) Testing</h1>
    <p><strong>Document ID:</strong> LAB-SOP-HIV-2025</p>
    <p><strong>Version:</strong> 1.0</p>
    <p><strong>Effective Date:</strong> January 1, 2025</p>
    <p><strong>Review Date:</strong> January 1, 2026</p>
    <p><strong>Department:</strong> Clinical Laboratory - Serology/Molecular Diagnostics</p>
</div>

<h2>1. PURPOSE AND SCOPE</h2>
<p>This Standard Operating Procedure (SOP) provides comprehensive guidelines for HIV testing using current CDC-recommended algorithms including 4th generation HIV-1/2 antigen/antibody combination assays, HIV-1/2 antibody differentiation assays, and HIV-1 nucleic acid amplification tests (NATs). This procedure encompasses screening, confirmatory testing, and acute HIV infection detection.</p>

<div class="info">
    <strong>Scope:</strong> This SOP applies to all laboratory personnel performing HIV testing using immunoassays, rapid tests, Western blot, and molecular methods within Kaiser Permanente laboratory facilities for screening, diagnosis, and monitoring of HIV infection in patients of all ages.
</div>

<h2>2. REGULATORY REQUIREMENTS AND COMPLIANCE</h2>
<div class="critical">
    <h3>Regulatory Standards:</h3>
    <ul>
        <li><strong>CLIA '88:</strong> High complexity testing requirements</li>
        <li><strong>CAP:</strong> Laboratory Accreditation Program virology/serology standards</li>
        <li><strong>FDA:</strong> Device regulations and cleared assays only</li>
        <li><strong>CDC:</strong> HIV testing algorithms and reporting guidelines</li>
        <li><strong>USPHS:</strong> Public Health Service HIV testing recommendations</li>
        <li><strong>Joint Commission:</strong> Patient safety and confidentiality standards</li>
        <li><strong>OSHA:</strong> Bloodborne pathogen and laboratory safety</li>
        <li><strong>Kaiser Permanente:</strong> Quality management system requirements</li>
        <li><strong>State/Local:</strong> HIV reporting and counseling requirements</li>
        <li><strong>HIPAA:</strong> Patient privacy and confidentiality</li>
    </ul>
</div>

<h2>3. PERSONNEL QUALIFICATIONS AND COMPETENCY</h2>
<div class="competency-req">
    <h3>Required Qualifications:</h3>
    <ul>
        <li>Medical Technologist (MT) or Medical Laboratory Scientist (MLS)</li>
        <li>Bachelor's degree in Clinical Laboratory Science or related field</li>
        <li>ASCP certification (MT, MLS) or equivalent</li>
        <li>Additional certification in virology/serology preferred</li>
        <li>Completion of Documents 14952_0 and 13792_0 competency assessments</li>
        <li>HIV testing-specific training and certification</li>
        <li>Understanding of HIV confidentiality requirements</li>
    </ul>

    <h3>Competency Requirements:</h3>
    <ul>
        <li>Initial competency assessment before independent testing</li>
        <li>Annual competency verification</li>
        <li>Proficiency testing participation</li>
        <li>Understanding of HIV biology and immunology</li>
        <li>Knowledge of testing algorithms and interpretation</li>
        <li>Confidentiality and counseling awareness</li>
        <li>Quality control procedures and troubleshooting</li>
        <li>Result reporting and follow-up requirements</li>
    </ul>
</div>

<h2>4. SAFETY PRECAUTIONS AND HAZARD COMMUNICATION</h2>
<div class="warning">
    <h3>Biological Safety:</h3>
    <ul>
        <li>Treat all specimens as potentially infectious for HIV and other bloodborne pathogens</li>
        <li>Use standard precautions for all blood and body fluids</li>
        <li>Wear appropriate PPE: gloves, lab coat, safety glasses</li>
        <li>Work in biological safety cabinet when required</li>
        <li>Proper disposal of biohazardous waste</li>
        <li>Hand hygiene before and after specimen handling</li>
        <li>No mouth pipetting or eating in laboratory areas</li>
        <li>Hepatitis B vaccination required for all personnel</li>
    </ul>

    <h3>Chemical Safety:</h3>
    <ul>
        <li>Review SDS for all reagents before use</li>
        <li>Store reagents according to manufacturer specifications</li>
        <li>Use fume hood for volatile substances</li>
        <li>Emergency procedures readily available</li>
        <li>Spill response materials accessible</li>
    </ul>

    <h3>Information Security:</h3>
    <ul>
        <li>Maintain strict confidentiality of all HIV test results</li>
        <li>Secure storage of patient information</li>
        <li>Limited access to HIV testing areas</li>
        <li>Compliance with HIPAA regulations</li>
        <li>Proper disposal of confidential documents</li>
    </ul>
</div>

<h2>5. INSTRUMENTATION AND EQUIPMENT</h2>
<h3>Primary Instruments:</h3>
<table>
    <tr>
        <th>Instrument</th>
        <th>Manufacturer</th>
        <th>Test Method</th>
        <th>Application</th>
    </tr>
    <tr>
        <td>Architect HIV Ag/Ab Combo</td>
        <td>Abbott</td>
        <td>4th generation screening</td>
        <td>Initial screening</td>
    </tr>
    <tr>
        <td>ADVIA Centaur HIV 1/O/2</td>
        <td>Siemens</td>
        <td>4th generation screening</td>
        <td>Initial screening</td>
    </tr>
    <tr>
        <td>Geenius HIV 1/2</td>
        <td>Bio-Rad</td>
        <td>Confirmatory immunoblot</td>
        <td>Supplemental testing</td>
    </tr>
    <tr>
        <td>Multispot HIV-1/HIV-2</td>
        <td>Bio-Rad</td>
        <td>Rapid differentiation</td>
        <td>Type differentiation</td>
    </tr>
    <tr>
        <td>Aptima HIV-1 RNA</td>
        <td>Hologic</td>
        <td>Nucleic acid amplification</td>
        <td>Acute infection detection</td>
    </tr>
    <tr>
        <td>OraQuick ADVANCE</td>
        <td>OraSure</td>
        <td>Rapid antibody test</td>
        <td>Point-of-care screening</td>
    </tr>
</table>

<h3>Supporting Equipment:</h3>
<ul>
    <li>Automated pipetting systems</li>
    <li>Centrifuges (refrigerated and benchtop)</li>
    <li>Incubators (37Â°C)</li>
    <li>Microplate washers and readers</li>
    <li>Refrigerators and freezers for storage</li>
</ul>

<h2>6. REAGENTS AND SUPPLIES</h2>
<h3>Screening Assay Reagents:</h3>
<ul>
    <li>HIV-1/2 antigen/antibody combo reagents</li>
    <li>Calibrators and controls</li>
    <li>Substrate and wash solutions</li>
    <li>Specimen diluent</li>
</ul>

<h3>Confirmatory Test Reagents:</h3>
<ul>
    <li>HIV-1/2 differentiation assay reagents</li>
    <li>Western blot or immunoblot strips</li>
    <li>Positive and negative controls</li>
    <li>Development solutions</li>
</ul>

<h3>Molecular Test Reagents:</h3>
<ul>
    <li>HIV-1 RNA amplification reagents</li>
    <li>Target capture reagents</li>
    <li>Internal controls</li>
    <li>Amplification and detection reagents</li>
</ul>

<h3>Rapid Test Supplies:</h3>
<ul>
    <li>Rapid test devices</li>
    <li>Sample collection materials</li>
    <li>Developer solutions</li>
    <li>Controls and timers</li>
</ul>

<h3>Storage Requirements:</h3>
<table>
    <tr>
        <th>Item</th>
        <th>Storage Temperature</th>
        <th>Stability</th>
        <th>Special Conditions</th>
    </tr>
    <tr>
        <td>Screening reagents</td>
        <td>2-8Â°C</td>
        <td>Until expiration</td>
        <td>Do not freeze</td>
    </tr>
    <tr>
        <td>Confirmatory reagents</td>
        <td>2-8Â°C</td>
        <td>Until expiration</td>
        <td>Protected from light</td>
    </tr>
    <tr>
        <td>Molecular reagents</td>
        <td>-20Â°C to -80Â°C</td>
        <td>Until expiration</td>
        <td>Avoid freeze-thaw cycles</td>
    </tr>
    <tr>
        <td>Rapid test kits</td>
        <td>2-30Â°C</td>
        <td>Until expiration</td>
        <td>Keep sealed and dry</td>
    </tr>
</table>

<h2>7. SPECIMEN COLLECTION AND HANDLING</h2>
<h3>Acceptable Specimens:</h3>
<ul>
    <li><strong>Serum:</strong> Red top or SST tubes (preferred)</li>
    <li><strong>Plasma:</strong> EDTA, heparin, or citrate tubes</li>
    <li><strong>Whole blood:</strong> For rapid testing</li>
    <li><strong>Oral fluid:</strong> For rapid testing (OraQuick)</li>
    <li><strong>Dried blood spots:</strong> For specialized testing</li>
</ul>

<h3>Collection Requirements:</h3>
<div class="info">
    <ul>
        <li>Proper patient identification with confidentiality measures</li>
        <li>Informed consent for HIV testing when required</li>
        <li>Appropriate tube selection and labeling</li>
        <li>Adequate sample volume (minimum 0.5 mL serum/plasma)</li>
        <li>Room temperature transport acceptable</li>
        <li>Refrigerate if testing delayed >4 hours</li>
    </ul>
</div>

<h3>Special Handling Requirements:</h3>
<ul>
    <li>Maintain chain of custody for forensic specimens</li>
    <li>Heat inactivation may be required for some assays</li>
    <li>Avoid repeated freeze-thaw cycles</li>
    <li>Label with biohazard indicators</li>
    <li>Secure transport to prevent exposure</li>
</ul>

<h3>Rejection Criteria:</h3>
<ul>
    <li>Unlabeled or mislabeled specimens</li>
    <li>Insufficient volume for testing</li>
    <li>Hemolyzed specimens (for some assays)</li>
    <li>Clotted plasma specimens</li>
    <li>Specimens with visible contamination</li>
    <li>Expired or improperly stored specimens</li>
</ul>

<h2>8. ANALYTICAL PROCEDURE</h2>
<h3>CDC Recommended HIV Testing Algorithm:</h3>
<ol>
    <li><strong>Initial Screening:</strong>
        <ul>
            <li>4th generation HIV-1/2 antigen/antibody combination immunoassay</li>
            <li>Detects HIV-1 p24 antigen and HIV-1/2 antibodies</li>
            <li>If negative: Report as HIV negative</li>
            <li>If positive or equivocal: Proceed to step 2</li>
        </ul>
    </li>
    <li><strong>Supplemental Testing:</strong>
        <ul>
            <li>HIV-1/2 antibody differentiation immunoassay</li>
            <li>Differentiates HIV-1 from HIV-2 antibodies</li>
            <li>If positive for HIV-1 or HIV-2: Report as HIV positive</li>
            <li>If negative or indeterminate: Proceed to step 3</li>
        </ul>
    </li>
    <li><strong>Nucleic Acid Testing:</strong>
        <ul>
            <li>HIV-1 RNA qualitative NAT</li>
            <li>Detects acute HIV-1 infection</li>
            <li>If positive: Acute HIV-1 infection</li>
            <li>If negative: HIV negative or indeterminate</li>
        </ul>
    </li>
</ol>

<h3>4th Generation Screening Procedure:</h3>
<ol>
    <li>Load specimens and controls onto automated platform</li>
    <li>System performs automated dilution and incubation</li>
    <li>Antigen-antibody capture and detection</li>
    <li>Signal measurement and interpretation</li>
    <li>Results calculated as signal-to-cutoff ratio</li>
</ol>

<h3>Rapid Testing Procedure:</h3>
<ol>
    <li>Verify test kit components and expiration</li>
    <li>Collect specimen according to manufacturer instructions</li>
    <li>Apply specimen to test device</li>
    <li>Add developer solution if required</li>
    <li>Read results at specified time intervals</li>
    <li>Interpret according to manufacturer's guide</li>
</ol>

<h2>9. QUALITY CONTROL</h2>
<div class="qc-table">
    <h3>QC Requirements:</h3>
    <table>
        <tr>
            <th>Test Type</th>
            <th>QC Frequency</th>
            <th>QC Materials</th>
            <th>Acceptable Range</th>
        </tr>
        <tr>
            <td>4th generation screening</td>
            <td>Each run</td>
            <td>Positive, negative, and cutoff controls</td>
            <td>Â±3 SD from target value</td>
        </tr>
        <tr>
            <td>Differentiation assay</td>
            <td>Each run</td>
            <td>HIV-1, HIV-2, and negative controls</td>
            <td>Expected positive/negative results</td>
        </tr>
        <tr>
            <td>Molecular testing</td>
            <td>Each run</td>
            <td>Positive, negative, and internal controls</td>
            <td>Within manufacturer specifications</td>
        </tr>
        <tr>
            <td>Rapid testing</td>
            <td>Each day of testing</td>
            <td>Positive and negative controls</td>
            <td>Expected visual results</td>
        </tr>
    </table>
</div>

<h3>Proficiency Testing:</h3>
<ul>
    <li>Participate in CAP or other approved PT programs</li>
    <li>Test all methods in routine use</li>
    <li>Quarterly challenges for screening and confirmatory tests</li>
    <li>100% accuracy required for HIV testing</li>
</ul>

<h3>QC Documentation:</h3>
<ul>
    <li>Levey-Jennings charts for quantitative assays</li>
    <li>Daily QC logs with results and actions</li>
    <li>Monthly QC summary reports</li>
    <li>Trend analysis and corrective actions</li>
</ul>

<h2>10. REFERENCE RANGES AND CRITICAL VALUES</h2>
<h3>Screening Assay Interpretation:</h3>
<table>
    <tr>
        <th>Result</th>
        <th>Signal/Cutoff Ratio</th>
        <th>Interpretation</th>
        <th>Action Required</th>
    </tr>
    <tr>
        <td>Negative</td>
        <td>&lt;1.0</td>
        <td>HIV antibody/antigen not detected</td>
        <td>Report as negative</td>
    </tr>
    <tr>
        <td>Positive</td>
        <td>â¥1.0</td>
        <td>HIV antibody/antigen detected</td>
        <td>Proceed to confirmatory testing</td>
    </tr>
    <tr>
        <td>Equivocal</td>
        <td>Near cutoff</td>
        <td>Indeterminate result</td>
        <td>Repeat testing, consider follow-up</td>
    </tr>
</table>

<h3>Confirmatory Testing Interpretation:</h3>
<table>
    <tr>
        <th>Differentiation Assay</th>
        <th>NAT Result</th>
        <th>Final Interpretation</th>
        <th>Reporting</th>
    </tr>
    <tr>
        <td>HIV-1 positive</td>
        <td>N/A</td>
        <td>HIV-1 antibodies detected</td>
        <td>HIV positive</td>
    </tr>
    <tr>
        <td>HIV-2 positive</td>
        <td>N/A</td>
        <td>HIV-2 antibodies detected</td>
        <td>HIV positive</td>
    </tr>
    <tr>
        <td>Negative/Indeterminate</td>
        <td>Positive</td>
        <td>Acute HIV-1 infection</td>
        <td>HIV positive (acute)</td>
    </tr>
    <tr>
        <td>Negative/Indeterminate</td>
        <td>Negative</td>
        <td>HIV infection unlikely</td>
        <td>HIV negative</td>
    </tr>
</table>

<div class="critical">
    <h3>Critical Values and Reporting:</h3>
    <ul>
        <li><strong>All positive HIV results:</strong> Critical value requiring immediate attention</li>
        <li><strong>Acute HIV infection:</strong> Extremely high infectivity period</li>
        <li><strong>Notification requirements:</strong> Follow state/local reporting guidelines</li>
        <li><strong>Confidentiality:</strong> Strict adherence to privacy regulations</li>
        <li><strong>Counseling referral:</strong> Connect patients with appropriate services</li>
        <li><strong>Partner notification:</strong> As per public health guidelines</li>
    </ul>
</div>

<h2>11. RESULT INTERPRETATION AND REPORTING</h2>
<h3>Reporting Guidelines:</h3>
<ul>
    <li><strong>Negative:</strong> "HIV-1/2 antibody and HIV-1 antigen not detected"</li>
    <li><strong>Positive:</strong> "HIV antibody detected" or "HIV-1 RNA detected"</li>
    <li><strong>Indeterminate:</strong> Include recommendation for follow-up testing</li>
    <li>Include testing methodology and limitations</li>
    <li>Provide appropriate counseling referrals</li>
</ul>

<h3>Special Considerations:</h3>
<ul>
    <li><strong>Window period:</strong> Early infection may not be detected</li>
    <li><strong>Immunocompromised patients:</strong> May have atypical serologic patterns</li>
    <li><strong>Infants born to HIV+ mothers:</strong> Maternal antibodies present</li>
    <li><strong>Recent vaccination:</strong> May cause false positive results</li>
    <li><strong>Cross-reactivity:</strong> Other conditions may interfere</li>
</ul>

<h3>Reflexive Testing:</h3>
<ul>
    <li>Automatic confirmatory testing for positive screening results</li>
    <li>NAT testing for indeterminate differentiation results</li>
    <li>Repeat testing for equivocal results</li>
    <li>Additional testing for discrepant results</li>
</ul>

<h2>12. TURNAROUND TIME (TAT) REQUIREMENTS</h2>
<table>
    <tr>
        <th>Test Type</th>
        <th>Priority</th>
        <th>Testing Time</th>
        <th>Total TAT</th>
    </tr>
    <tr>
        <td>Screening only (negative)</td>
        <td>Routine</td>
        <td>2 hours</td>
        <td>4 hours</td>
    </tr>
    <tr>
        <td>Complete algorithm</td>
        <td>Routine</td>
        <td>4-6 hours</td>
        <td>8-12 hours</td>
    </tr>
    <tr>
        <td>Rapid testing</td>
        <td>STAT</td>
        <td>15-20 minutes</td>
        <td>30 minutes</td>
    </tr>
    <tr>
        <td>Molecular testing</td>
        <td>Same day</td>
        <td>3-4 hours</td>
        <td>6-8 hours</td>
    </tr>
    <tr>
        <td>Send-out confirmatory</td>
        <td>Routine</td>
        <td>1-3 days</td>
        <td>2-5 days</td>
    </tr>
</table>

<h2>13. TROUBLESHOOTING</h2>
<h3>Common Issues and Solutions:</h3>
<table>
    <tr>
        <th>Problem</th>
        <th>Possible Cause</th>
        <th>Solution</th>
        <th>Prevention</th>
    </tr>
    <tr>
        <td>False positive screening</td>
        <td>Cross-reactive antibodies</td>
        <td>Confirmatory testing required</td>
        <td>Follow testing algorithm</td>
    </tr>
    <tr>
        <td>Indeterminate differentiation</td>
        <td>Early seroconversion</td>
        <td>Perform HIV-1 NAT</td>
        <td>Consider acute infection</td>
    </tr>
    <tr>
        <td>Discrepant results</td>
        <td>Specimen mix-up, technical error</td>
        <td>Repeat with fresh specimen</td>
        <td>Proper specimen handling</td>
    </tr>
    <tr>
        <td>Weak positive signals</td>
        <td>Low antibody levels</td>
        <td>Repeat testing, consider NAT</td>
        <td>Fresh specimens preferred</td>
    </tr>
    <tr>
        <td>Equipment malfunction</td>
        <td>Instrument failure</td>
        <td>Use backup method</td>
        <td>Preventive maintenance</td>
    </tr>
</table>

<h2>14. MAINTENANCE AND CALIBRATION</h2>
<h3>Daily Maintenance:</h3>
<ul>
    <li>Instrument startup and performance verification</li>
    <li>Quality control testing and review</li>
    <li>Temperature monitoring verification</li>
    <li>Reagent level and expiration checks</li>
    <li>Waste container monitoring</li>
</ul>

<h3>Weekly Maintenance:</h3>
<ul>
    <li>System cleaning and decontamination</li>
    <li>Calibration verification</li>
    <li>QC trend analysis</li>
    <li>Reagent inventory and ordering</li>
</ul>

<h3>Monthly Maintenance:</h3>
<ul>
    <li>Comprehensive instrument maintenance</li>
    <li>Performance verification studies</li>
    <li>Documentation review and archiving</li>
    <li>Staff competency assessment</li>
</ul>

<h2>15. DOCUMENTATION AND RECORD KEEPING</h2>
<h3>Required Documentation:</h3>
<ul>
    <li>Daily worksheets and result logs</li>
    <li>Quality control records and charts</li>
    <li>Calibration and maintenance logs</li>
    <li>Temperature monitoring records</li>
    <li>Proficiency testing results</li>
    <li>Critical value notifications</li>
    <li>Confirmatory testing results</li>
    <li>Training and competency records</li>
</ul>

<h3>Confidentiality Requirements:</h3>
<ul>
    <li>Secure storage of all HIV-related documents</li>
    <li>Limited access to authorized personnel only</li>
    <li>Encrypted electronic storage systems</li>
    <li>Secure disposal of confidential materials</li>
    <li>Audit trails for access monitoring</li>
</ul>

<h3>Retention Periods:</h3>
<ul>
    <li><strong>Patient results:</strong> 7 years (or per state requirements)</li>
    <li><strong>QC records:</strong> 2 years</li>
    <li><strong>Confirmatory results:</strong> 10 years</li>
    <li><strong>Proficiency testing:</strong> 2 years</li>
    <li><strong>Training records:</strong> 2 years after termination</li>
</ul>

<h2>16. TRAINING AND COMPETENCY ASSESSMENT</h2>
<div class="competency-req">
    <h3>Training Components:</h3>
    <ul>
        <li>HIV virology and immunology</li>
        <li>Disease progression and clinical manifestations</li>
        <li>Testing methodologies and algorithms</li>
        <li>Quality control and quality assurance</li>
        <li>Result interpretation and limitations</li>
        <li>Confidentiality and counseling considerations</li>
        <li>Safety procedures and emergency protocols</li>
        <li>Regulatory compliance requirements</li>
    </ul>

    <h3>Competency Assessment Methods:</h3>
    <ul>
        <li>Direct observation of testing procedures</li>
        <li>Written examination on HIV testing</li>
        <li>Proficiency testing performance</li>
        <li>Problem-solving scenario evaluation</li>
        <li>Quality control interpretation</li>
        <li>Confidentiality protocol assessment</li>
    </ul>

    <h3>Continuing Education:</h3>
    <ul>
        <li>Annual HIV testing updates</li>
        <li>New technology and methodology training</li>
        <li>Counseling and communication skills</li>
        <li>Regulatory and guideline updates</li>
    </ul>
</div>

<h2>17. BACKUP PROCEDURES AND CONTINGENCY PLANS</h2>
<div class="warning">
    <h3>Primary Backup Laboratory:</h3>
    <p><strong>MOB Laboratory</strong><br>
    Phone: 301-555-2000<br>
    Contact: Laboratory Director<br>
    Expected TAT: Add 2-4 hours for transport and processing</p>

    <h3>Equipment Failure Contingencies:</h3>
    <ul>
        <li><strong>Primary platform failure:</strong> Use backup instrumentation</li>
        <li><strong>Confirmatory test unavailable:</strong> Send to reference laboratory</li>
        <li><strong>Molecular testing down:</strong> Alternative NAT methods</li>
        <li><strong>Rapid testing backup:</strong> For urgent results</li>
        <li><strong>Power outage:</strong> Emergency generator and manual procedures</li>
    </ul>

    <h3>Critical Situations:</h3>
    <ul>
        <li>Maintain cold chain for specimens during outages</li>
        <li>Manual result reporting systems available</li>
        <li>Emergency contact procedures for critical results</li>
        <li>Backup counseling and referral services</li>
    </ul>
</div>

<h2>18. PROFICIENCY TESTING</h2>
<h3>PT Program Requirements:</h3>
<ul>
    <li><strong>Provider:</strong> CAP, CDC, or approved PT provider</li>
    <li><strong>Frequency:</strong> 3 times per year minimum</li>
    <li><strong>Methods tested:</strong> All screening and confirmatory methods</li>
    <li><strong>Acceptable performance:</strong> 100% accuracy required</li>
</ul>

<h3>PT Challenge Areas:</h3>
<ul>
    <li>HIV-1 and HIV-2 antibody detection</li>
    <li>HIV-1 p24 antigen detection</li>
    <li>Acute infection detection</li>
    <li>Cross-reactivity and interference</li>
    <li>Low-level positive specimens</li>
</ul>

<h3>PT Failure Response:</h3>
<ol>
    <li>Immediate investigation and root cause analysis</li>
    <li>Review of all patient results since last successful PT</li>
    <li>Corrective action implementation</li>
    <li>Retesting and verification of correction</li>
    <li>Documentation and regulatory notification</li>
    <li>Additional training if required</li>
</ol>

<h2>19. PROCEDURE UPDATES AND REVISIONS</h2>
<h3>Review Schedule:</h3>
<ul>
    <li><strong>Annual review:</strong> January of each year</li>
    <li><strong>Triggered reviews:</strong> Algorithm changes, new methods</li>
    <li><strong>Regulatory updates:</strong> CDC guideline changes</li>
    <li><strong>Version control:</strong> All changes documented and approved</li>
</ul>

<h3>Change Control Process:</h3>
<ol>
    <li>Proposed changes submitted to Laboratory Director</li>
    <li>Clinical and technical review</li>
    <li>Method validation studies if required</li>
    <li>Staff training and competency updates</li>
    <li>Implementation with effective date</li>
    <li>Post-implementation monitoring</li>
</ol>

<h2>20. REGULATORY COMPLIANCE MONITORING</h2>
<h3>Compliance Activities:</h3>
<ul>
    <li>Monthly quality indicator reviews</li>
    <li>Quarterly HIV testing assessments</li>
    <li>Annual compliance audit</li>
    <li>Confidentiality compliance monitoring</li>
    <li>CDC algorithm compliance verification</li>
</ul>

<h3>Key Performance Indicators:</h3>
<table>
    <tr>
        <th>Indicator</th>
        <th>Target</th>
        <th>Monitoring Frequency</th>
        <th>Responsible Party</th>
    </tr>
    <tr>
        <td>Algorithm Compliance</td>
        <td>100%</td>
        <td>Weekly</td>
        <td>Technical Supervisor</td>
    </tr>
    <tr>
        <td>TAT Compliance</td>
        <td>&gt;95%</td>
        <td>Daily</td>
        <td>Shift Supervisor</td>
    </tr>
    <tr>
        <td>Proficiency Testing</td>
        <td>100% acceptable</td>
        <td>Per event</td>
        <td>Laboratory Director</td>
    </tr>
</table>

<h2>21. WASTE MANAGEMENT AND ENVIRONMENTAL CONSIDERATIONS</h2>
<h3>Waste Categories:</h3>
<ul>
    <li><strong>Biohazardous waste:</strong> All specimens and contaminated materials</li>
    <li><strong>Sharps waste:</strong> Pipette tips, broken glass</li>
    <li><strong>Chemical waste:</strong> Reagents and solvents</li>
    <li><strong>Confidential waste:</strong> Patient information requiring secure disposal</li>
</ul>

<h3>Special Disposal Requirements:</h3>
<ul>
    <li>Inactivation of HIV-positive specimens before disposal</li>
    <li>Secure shredding of confidential documents</li>
    <li>Tracked disposal of controlled materials</li>
    <li>Environmental monitoring for chemical waste</li>
</ul>

<h2>22. CONTINUOUS IMPROVEMENT</h2>
<h3>Quality Improvement Activities:</h3>
<ul>
    <li>Algorithm performance evaluations</li>
    <li>Workflow optimization studies</li>
    <li>Error reduction initiatives</li>
    <li>Technology assessment and adoption</li>
    <li>Patient satisfaction and counseling effectiveness</li>
</ul>

<h3>Innovation Opportunities:</h3>
<ul>
    <li>Point-of-care molecular testing</li>
    <li>Digital connectivity and reporting</li>
    <li>Artificial intelligence for result interpretation</li>
    <li>Home collection and testing programs</li>
</ul>

<h2>23. CONTACT INFORMATION AND REFERENCES</h2>
<h3>Key Contacts:</h3>
<table>
    <tr>
        <th>Role</th>
        <th>Name</th>
        <th>Phone</th>
        <th>Email</th>
    </tr>
    <tr>
        <td>Laboratory Director</td>
        <td>Dr. [Name]</td>
        <td>XXX-XXX-XXXX</td>
        <td>[email]</td>
    </tr>
    <tr>
        <td>Serology Supervisor</td>
        <td>[Name], MT(ASCP)</td>
        <td>XXX-XXX-XXXX</td>
        <td>[email]</td>
    </tr>
    <tr>
        <td>Molecular Diagnostics Supervisor</td>
        <td>[Name], MLS(ASCP)</td>
        <td>XXX-XXX-XXXX</td>
        <td>[email]</td>
    </tr>
    <tr>
        <td>HIV Counseling Services</td>
        <td>[Name]</td>
        <td>XXX-XXX-XXXX</td>
        <td>[email]</td>
    </tr>
</table>

<h3>References:</h3>
<ul>
    <li>CDC Guidelines for HIV Testing in Clinical Settings</li>
    <li>Association of Public Health Laboratories HIV Testing Guidelines</li>
    <li>CLSI QMS11-A3: Nucleic Acid Testing</li>
    <li>CLSI I/LA21-A2: Immunoassay Quality Control</li>
    <li>CAP Virology and Serology Checklist</li>
    <li>FDA Guidance for HIV Testing</li>
    <li>Manufacturer's package inserts and operator manuals</li>
    <li>Kaiser Permanente HIV Testing and Counseling Policy</li>
    <li>Clinical Laboratory Improvement Amendments (CLIA) Regulations</li>
</ul>

<div class="signature-section">
    <h3>APPROVAL SIGNATURES</h3>
    <table>
        <tr>
            <th>Role</th>
            <th>Signature</th>
            <th>Date</th>
        </tr>
        <tr>
            <td>Laboratory Director</td>
            <td>_________________________</td>
            <td>_____________</td>
        </tr>
        <tr>
            <td>Serology Supervisor</td>
            <td>_________________________</td>
            <td>_____________</td>
        </tr>
        <tr>
            <td>Quality Assurance Manager</td>
            <td>_________________________</td>
            <td>_____________</td>
        </tr>
    </table>
</div>

<div class="footer">
    <p><strong>Kaiser Permanente Laboratory Services</strong><br>
    This document is controlled and subject to change. Verify current version before use.<br>
    Document ID: LAB-SOP-HIV-2025 | Version 1.0 | Page 1 of 1</p>
</div>

</body>
</html>